Enter vial size (5–60 mg), BAC water volume, and weekly dose to get concentration, syringe units to draw, and doses per vial. Includes the 6-tier titration schedule (2.5–15 mg weekly), vial size comparison, and syringe capacity warnings. Verify tirzepatide quality with independent lab test data on Peptigrity.
The FDA-approved titration protocol for tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) starts at 2.5 mg once weekly and increases by 2.5 mg every 4 weeks to a maximum of 15 mg weekly. Compounded lyophilised tirzepatide follows the same titration tiers.
| Tier | Weekly dose | Weeks | @ 5 mg/mL | @ 10 mg/mL | @ 15 mg/mL |
|---|---|---|---|---|---|
| Tier 1 (start) | 2.5 mg | Weeks 1–4 | 50 u | 25 u | ~17 u |
| Tier 2 | 5 mg | Weeks 5–8 | 100 u | 50 u | ~33 u |
| Tier 3 | 7.5 mg | Weeks 9–12 | Exceeds | 75 u | 50 u |
| Tier 4 | 10 mg | Weeks 13–16 | Exceeds | 100 u | ~67 u |
| Tier 5 | 12.5 mg | Weeks 17–20 | Exceeds | Exceeds | ~83 u |
| Tier 6 (max) | 15 mg | Week 21+ | Exceeds | Exceeds | 100 u |
At 5 mg/mL concentration (10 mg vial + 2 mL BAC water), doses above 5 mg exceed a standard 100-unit syringe's capacity. Users titrating beyond 5 mg must increase the concentration (use less BAC water) or split the dose across 2 draws. The calculator above flags syringe capacity warnings automatically.
| Vial size | @ 2.5 mg/wk | @ 5 mg/wk | @ 10 mg/wk | @ 15 mg/wk | Best for |
|---|---|---|---|---|---|
| 5 mg | 2 weeks | 1 week | — | — | Trial / starting dose |
| 10 mg | 4 weeks | 2 weeks | 1 week | — | Tiers 1–2 |
| 15 mg | 6 weeks | 3 weeks | 1.5 weeks | 1 week | Single-tier coverage |
| 30 mg | 12 weeks | 6 weeks | 3 weeks | 2 weeks | Multi-week protocols |
| 60 mg | 24 weeks | 12 weeks | 6 weeks | 4 weeks | Extended protocols |
Shelf life constraint: Reconstituted tirzepatide lasts approximately 28 days. Larger vials may outlast the stability window. Reconstitute only what you need for 4 weeks. For price comparisons, use the cost-per-dose calculator.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | Dual: GIP + GLP-1 | GLP-1 only |
| Starting dose | 2.5 mg weekly | 0.25 mg weekly |
| Maintenance range | 5–15 mg weekly | 1.0–2.4 mg weekly |
| Maximum dose | 15 mg weekly | 2.4 mg weekly (Wegovy) |
| Titration steps | +2.5 mg every 4 weeks | +0.25–0.5 mg every 4 weeks |
| Common vial sizes | 5, 10, 15, 30, 60 mg | 2, 3, 5, 10 mg |
At 5 mg/mL (10 mg vial + 2 mL BAC water), 2.5 mg = 50 units. At 10 mg/mL (10 mg vial + 1 mL BAC water), 2.5 mg = 25 units. At 15 mg/mL, 2.5 mg = approximately 17 units. Use the calculator above with your specific vial and BAC water volume for the exact draw.
1 mL produces 10 mg/mL — suitable for doses up to 10 mg in a single 100-unit draw. 2 mL produces 5 mg/mL — easier to measure small starting doses (2.5 mg = 50 units) but exceeds syringe capacity above 5 mg. Choose based on your current and planned titration tier.
Reconstituted tirzepatide stored at 2–8°C (standard refrigerator) remains stable for approximately 28 days. Unreconstituted lyophilised powder stored at −20°C maintains integrity for 3–6 months.
All three contain the same 39-amino-acid dual GIP/GLP-1 receptor agonist. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is approved for weight management. Both ship as pre-filled pens. Compounded tirzepatide is produced by pharmacies under FDA 503A/503B regulations as lyophilised powder requiring reconstitution.
Divide your dose (in mg) by the concentration (in mg/mL), then multiply by 100. Example: 5 mg ÷ 10 mg/mL = 0.5 mL × 100 = 50 units. The calculator performs this conversion automatically.
At 2.5 mg/week: 12 doses. At 5 mg/week: 6 doses. At 10 mg/week: 3 doses. At 15 mg/week: 2 doses. However, reconstituted tirzepatide is stable for approximately 28 days — so plan reconstitution in portions if your protocol extends beyond that.